Advertisement

Topics

Molecular Response LLC Company Profile

12:53 EDT 23rd October 2018 | BioPortfolio

Molecular Response is a leader in advancing targeted therapeutics through intelligently designed, clinically validated companion diagnostics. Our goal is to reduce risk and cost of therapeutic drug development for our partners by translating clinically relevant molecular response marker data into high-value knowledge while fully integrated into existing pharmaceutical development processes and programs; Our results reduce risk and cost of drug development and allow for the most informed decisions with best chance of success to advance therapeutic programs.


News Articles [996 Associated News Articles listed on BioPortfolio]

Molecular Partners says 5 of 8 patients responded in multiple myeloma trial

ZURICH (Reuters) - Molecular Partners said on Friday that five of eight patients with advanced multiple myeloma in a Phase II study showed an objective response to a combination therapy that includes ...

Hybrigenics (ALHYG) - Leukaemia pipeline advances with new data

Edison Investment Research - Pharmaceutical & healthcare - Hybrigenics: Hybrigenics has published data from a Phase II study in chronic myeloid leukaemia (CML). After one year of treatment, 40% of pat...

Molecular Templates' NHL candidate shows higher response rates with low baseline Rituxan levels

Keap1–MCM3 interaction is a potential coordinator of molecular machineries of antioxidant response and genomic DNA replication in metazoa

New Research Provides Expanded Insights into the Brain's Response to Opioids

NewsResearchers have developed a tool that gives deeper insights into the brain's response to opioids. Using mass spectrometry, they determined changes of proteins' phosphorylation patterns - the mole...

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

The Molecular Autopsy: Not Ready Yet for Prime Time

Although I have always been a strong advocate for sophisticated molecular and genomic testing, I tend to get a severe case of indigestion when I see references to the molecular autopsy (see: Can Inter...

Drugs and Medications [2 Associated Drugs and Medications listed on BioPortfolio]

Nilandron [sanofi-aventis U.S. LLC]

NILANDRON (nilutamide)Tablets

Salsalate [Libertas Pharma, Inc.]

Salsalate Tablets, USP 500 and 750 mgRx Only

PubMed Articles [2585 Associated PubMed Articles listed on BioPortfolio]

Early molecular response ≤1% has strong prognostic impact for CML patients that switch to second-line therapy with BCR-ABL1 ≤10% and no major molecular response.

Finding Sugar in the Pantry: How Galectins Detect and Signal Lysosomal Damage.

In this issue of Molecular Cell, Jia et al. (2018) identify a lysosomal damage-response pathway centered on galectin 8 and 9 that feeds back on mTORC1 signaling. In response to lysosome-damaging agen...

Comparative analyses of nilotinib versus high-dose imatinib versus sustained standard-dose imatinib in patients with chronic phase chronic myeloid leukemia following suboptimal molecular response to first-line imatinib.

The aim of this study was to investigate the efficacy of nilotinib (NIL) versus high-dose imatinib (IM) versus sustained standard-dose IM for patients with chronic myeloid leukemia (CML) with suboptim...

Molecular signature of response to preoperative radiotherapy in locally advanced breast cancer.

Radiation therapy is an indispensable part of various treatment modalities for breast cancer. Specifically, for non-inflammatory locally advanced breast cancer (LABC) patients, preoperative radiothera...

An Overview of Molecular Profiles in Ulcerative Colitis-Related Cancer.

Ulcerative colitis (UC) is an independent risk factor of colorectal cancer (CRC). Both genetic and epigentic events induce a unique molecular profile during the development from UC to UC-related CRC (...

Clinical Trials [3897 Associated Clinical Trials listed on BioPortfolio]

Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib

This exploratory study will evaluate the change in molecular response in chronic myelogenous leukemia - chronic phase patients with a complete cytogenetic response and have a suboptimal mo...

Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response

Imatinib mesylate is standard treatment of Chronic myeloid leukaemia, complete cytogenetic response is obtained in most of cases but molecular response concerned only a small part of the p...

Molecular Processes of the Relaxation Response in Older Adults

The purpose of this study is to examine the molecular (nitric oxide) and biochemical (epinephrine, norepinephrine, cortisol and ACTH) parameters that are associated with RR elicitation and...

Retrospective Study Assessing Molecular Features Predicting Response to Cetuximab

The primary objective is to identify molecular features predicting response or resistance to cetuximab

Molecular Response After Concurrent Exercise With Low Glycogen

This is a randomized, counterbalanced crossover design, in which 14 male subjects will complete two experimental trials. Each trial will be separated by a minimum of at least 12 days (rang...

Companies [1297 Associated Companies listed on BioPortfolio]

Molecular Response LLC

Molecular Response is a leader in advancing targeted therapeutics through intelligently designed, clinically validated companion diagnostics. Our goal is to reduce risk and...

Molecular Response

Molecular Response is a leader in advancing targeted therapeutics through intelligently designed, clinically validated companion diagnostics. Our goal is to reduce risk and increa...

Church & Dwight, Co., Inc.

Church and Dwight, Co., Inc., headquartered in Princeton, NJ, distributes First Response Early Result Pregnancy Test and other First Response products, including First Response Gold Digital, First Res...

Gene Network Sciences, Inc.

Gene Network Sciences (http://www.gnsbiotech.com/) is a leader in biosimulation with its ability to derive molecular mechanisms of drugs and diseases directly from molecular profiling and clinical dat...

Nova Molecular Incorporated

Nova Molecular Inc. (NMI) is a Montreal based CNS drug discovery company focused on understanding neuronal degeneration, disease progression, repair mechanisms, therapeutic response and development ba...

More Information about "Molecular Response LLC" on BioPortfolio

We have published hundreds of Molecular Response LLC news stories on BioPortfolio along with dozens of Molecular Response LLC Clinical Trials and PubMed Articles about Molecular Response LLC for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Molecular Response LLC Companies in our database. You can also find out about relevant Molecular Response LLC Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record